The global fibromyalgia market size was valued at around USD 1,919 million in 2021 and is anticipated to expand at a CAGR of 9.3% during the forecast period, 2022–2030. The growth of the market is attributed to increasing prevalence of fibromyalgia.
Fibromyalgia is a musculoskeletal disorder that affects nearly 3-6% of the global population, according to US National Fibromyalgia Association. It causes fatigue, pain, sleep problems, and localized tenderness. Symptoms of fibromyalgia include headache and impaired attention. Healthy diet, regular exercise, and adequate sleep are recommended along with medication to treat fibromyalgia. Milnacipran, Pregabalin, and Duloxetine are some drugs that are prescribed for the treatment of fibromyalgia. The cause of fibromyalgia is unknown; however, it is thought to be caused by persistent infection, as well as physical and mental stress. Females are more susceptible to fibromyalgia than males. Fibromyalgia can also be caused by rheumatoid arthritis, osteoarthritis, or lupus.
Pharmaceutical and biotech laboratories, in association with governments across the globe, are working to combat the COVID-19 pandemic, from vaccine research to pharmaceutical supply chain planning. Biotechnology and pharmaceutical industries are expected to grow significantly in the future, due to the need for COVID-19 vaccines and treatment medication. This is projected to have a positive influence on the fibromyalgia market.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing government initiatives that guide manufacturers and healthcare professionals regarding fibromyalgia is expected to drive the market.
- Rising incidence of traumatic stress and increasing burden of chronic pain are projected to propel the market during the forecast period.
- High adoption of off-label drugs is anticipated to hinder the market.
- Lack of awareness regarding the disease is expected to hamper the market in the coming years.
- Advancement in healthcare technology and launch of novel pipeline drugs in the market is projected to create lucrative opportunities for market players.
Scope of the Report
The report on the global fibromyalgia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Fibromyalgia Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2021 |
| Historic Data | 2019–2020 |
| Forecast Period | 2022–2030 |
| Segmentation | Diagnosis (Blood Tests [Erythrocyte Sedimentation Rate, Complete Blood Count, Cyclic Citrullinated Peptide Test, Rheumatoid Factor, Thyroid Function Tests, Celiac Serology, Anti-Nuclear Antibody, and Vitamin D], and Others), Treatments (Medication [Pain Relievers, Anti-seizure Drugs, and Antidepressants], Therapy [Occupational therapy, Physical therapy, and Counselling], and Others), and End-users (Specialty Clinics, Hospitals, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Teva Pharmaceuticals Industries Ltd.; Novartis AG; Sun Pharmaceuticals; Astellas Pharma Inc.; Pfizer, Inc.; Eli Lilly and Company; Allergan; Tonix Pharmaceuticals; and Aptinyx |
Market Segment Insights
Complete blood count segment to expand at a considerable CAGR
On the basis of diagnosis, the fibromyalgia market is bifurcated into blood tests and others. The blood test segment is further classified as erythrocyte sedimentation rate, complete blood count, cyclic citrullinated peptide test, rheumatoid factor, thyroid function tests, celiac serology, anti-nuclear antibody, and vitamin D. The complete blood count segment is projected to expand at a considerable CAGR during the forecast period. The complete blood count test or C-reactive protein test aids in finding diseases that cause inflammation, such as polymyalgia rheumatica. The thyroid function tests segment is anticipated to account for a major market share during the forecast period. The fibromyalgia disease worsens the symptoms of the thyroid disease, therefore thyroid function testing is usually done during evaluation for possible fibromyalgia.
Medication segment to hold a significant share of the market
Based on treatments, the market is divided into medication, therapy, and others. The medication segment is further segregated into pain relievers, anti-seizure drugs, and antidepressants. The therapy segment is further categorized as occupational therapy, physical therapy, and counselling. The medication segment is expected to hold a significant share of the market in the coming years, as medicine helps patients in alleviating fatigue and pain. The therapy segment accounts for a significant market share, to achieve fast recovery and effective results.
Hospitals segment to expand at a substantial CAGR
On the basis of end-users, the fibromyalgia market is segregated into specialty clinics, hospitals, and others. The hospitals segment is anticipated to expand at a substantial CAGR during the forecast period, owing to availability of specialized healthcare experts and advanced infrastructure. The specialty clinics segment is expected to hold a significant share of the market, due to increasing need for regular check-up and follow up treatment.
North America is anticipated to constitute a key market share
In terms of regions, the fibromyalgia market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to well-established healthcare system in the region. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to availability of advanced approved products in the region to manage the disorder.
Segments
The global fibromyalgia market has been segmented on the basis of
Diagnosis
- Blood Tests
- Erythrocyte Sedimentation Rate
- Complete Blood Count
- Cyclic Citrullinated Peptide Test
- Rheumatoid Factor
- Thyroid Function Tests
- Celiac Serology
- Anti-Nuclear Antibody
- Vitamin D
- Others
Treatments
- Medication
- Pain Relievers
- Anti-seizure Drugs
- Antidepressants
- Therapy
- Occupational therapy
- Physical therapy
- Counselling
- Others
End-users
- Specialty Clinics
- Hospitals
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Sun Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer, Inc.
- Eli Lilly and Company
- Allergan
- Tonix Pharmaceuticals
- Aptinyx
Competitive Landscape
Key players competing in the global fibromyalgia market are Teva Pharmaceuticals Industries Ltd.; Novartis AG; Sun Pharmaceuticals; Astellas Pharma Inc.; Pfizer, Inc.; Eli Lilly and Company; Allergan; Tonix Pharmaceuticals; and Aptinyx.
Key players realize the market potential and are actively working to expand their offerings. Teva Pharmaceuticals' AJOVY, is now undergoing a phase 2 clinical study for the treatment of fibromyalgia in the US. Tonix Pharamceuticals and Teva are important competitors in the industry, due to their robust pipeline and product lineups.
Request For Customization
Enquiry Before Buying
Speak With Analyst
